Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Location: United States, Massachusetts, Cambridge
Total raised: $60M
Investors 3
| Date | Name | Website |
| 23.10.2020 | Alta Partn... | altapartne... |
| - | RA Capital... | racap.com |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.10.2020 | Series A | $52M | - |
| 10.09.2012 | Series A | $8M | - |
Mentions in press and media 9
| Date | Title | Description |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 25.10.2024 | The Week’s 10 Biggest Funding Rounds: Seaport Therapeutics And Zip Top Big Money Week | 4 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 26.10.2020 | StartUPDATES: New developments from healthcare startups | “To break the cost curve for both employers and employees, we went all-in on building a health plan that provides the tools needed to see cost and quality comparisons, as well as treatment path options across conditions. And we removed unne... |
| 26.10.2020 | Be Biopharma Raises $52M in Series A Financing | Be Biopharma, a Cambridge, MA-based company developing B cells as medicines, raised $52m in Series A financing. The round was led by Atlas Venture and RA Capital Management joined by Alta Partners, Longwood Fund and Takeda Ventures. The com... |
| 10.09.2012 | Annovation Biopharma Raises $8M in Series A Funding | Annovation Biopharma, a Wayland, Massachusetts-based biotechnology company focused on creating more effective, safer therapies for anesthesia and critical care, has raised $8m in a Series A funding. The round was led by Atlas Venture, Partn... |
| 10.09.2012 | Annovation Biopharma Snares $8M Series A | CAMBRIDGE, MA, Biotechnology company focused on creating more effective, safer therapies for anesthesia and critical care, has raised $8M in a Series A financing. >> Click here for more funding data on Annovation Biopharma >>... |
| - | Be Bio Announces Appointment of Cell and Gene Therapy Veterans Joanne Smith-Farrell, Ph.D., as Chief Executive Officer and Rick Morgan, Ph.D., as Chief Scientific Officer | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 16, 2021-- Be Biopharma (“Be Bio”), whose mission is to pioneer the emerging new category of engineered B cells as medicines, today announced that Joanne Smith-Farrell, Ph.D., has been appointed Chief ... |
| - | StartUPDATES: New developments from healthcare startups | Bind announced a $105 million Series B funding round, as investors show continued confidence in the Bind approach to health insurance innovation and market interest. Bind believes people deserve to see treatment options and compare costs in... |